12:00 AM
Nov 01, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Onbrez Breezhaler indacaterol regulatory update

Novartis disclosed in its 3Q10 earnings that it submitted new data to FDA in September supporting the 75 and 150 µg doses of indacaterol as...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >